FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Azor shows efficacy in difficult to treat patient groups

Data presented at ASH shows that Azor (amlodipine and olmesartan medoxomil) safely and effectively lowered blood pressure, especially in several key difficult to treat patient groups such as in those of African and Hispanic/Latino decent

Forest and Daiichi Sankyo end Azor co promotion agreement

Forest has terminated it’s co-promotion agreement for Azor (amlodipine and olmesartan medoxomil) with Daiichi Sankyo. Forest has determined that its resources will be better utilized in providing additional support for Forest’s currently marketed products.